The Use of Ibrutinib in Extranodal Marginal Zone Lymphoma of the Ocular Adnexa with Multifocal Disease that is Refractory to Rituximab
DOI:
https://doi.org/10.46570/utjms.vol12-2024-626Keywords:
Extranodal Marginal Zone Lymphoma, EMZL, Conjunctival Lymphoma, Rituximab, IbrutinibAbstract
Tumors of the ocular adnexa been well documented. The most common ocular adnexal lymphoma is extranodal
marginal zone B-cell lymphoma (EMZL), with about a quarter of those occurring in the conjunctiva. We present a
case with a patient suspected ocular EMZL, confirmed with biopsy. Positron emission tomography (PET) scan was
performed to evaluate for distal lesions and the patient was found to have multiple hypermetabolic lesions
throughout the body. Treatment with rituximab was initiated, and after four weekly treatments, subsequent PET
scan showed that the original hypermetabolic lesions remained and new lesions appeared. Rituximab was stopped
and ibrutinib started. After eight months of ibrutinib treatment, PET scan showed that the original hypermetabolic
lesions had disappeared. 19 months from initiation of treatment, a new hilar lesion was found. This progressed
into bilateral hilar and mediastinal lymphadenopathy, which was seen on PET scan performed 29 months into
treatment. These findings remained stable 35 months post-initiation of treatment. The use of ibrutinib in this
patient that initially presented with a lesion in the conjunctiva resulted in an initial resolution of the original
systemic hypermetabolic regions on PET scan. While more studies are needed on ibrutinib in the treatment of
ocular EMZL, physicians should be aware of the presentation of this disease and the range of treatment modalities.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alexander Luna, Mary Shenouda (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
